Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction

Open access

Abstract

Key points: Skeletal muscle fatigue limits performance in various physical activities, with exercise intolerance being a key symptom in a broad spectrum of diseases. We investigated whether a small molecule fast skeletal troponin activator (FSTA), CK‐2066260, can mitigate muscle fatigue by reducing the cytosolic free [Ca 2+] required to produce a given submaximal force and hence decreasing the energy requirement. Isolated intact single mouse muscle fibres and rat muscles in‐situ treated with CK‐2066260 showed improved muscle endurance., which was accompanied by decreased ATP demand and reduced glycogen usage. CK‐2066260 treatment improved in‐vivo exercise capacity in healthy rats and in a rat model of peripheral artery insufficiency. In conclusion, we show that the FSTA CK‐2066260 effectively counteracts muscle fatigue in rodent skeletal muscle in vitro, in situ, and in vivo. This may translate to humans and provide a promising pharmacological treatment to patients suffering from severe muscle weakness and exercise intolerance. Skeletal muscle fatigue limits performance during physical exercise and exacerbated muscle fatigue is a prominent symptom among a broad spectrum of diseases. The present study investigated whether skeletal muscle fatigue is affected by the fast skeletal muscle troponin activator (FSTA) CK‐2066260, which increases myofibrillar Ca 2+ sensitivity and amplifies the submaximal force response. Because more force is produced for a given Ca 2+, we hypothesized that CK‐2066260 could mitigate muscle fatigue by reducing the energetic cost of muscle activation. Isolated single mouse muscle fibres were fatigued by 100 repeated 350 ms contractions while measuring force and the cytosolic free [Ca 2+] or [Mg 2+] ([Mg 2+]i). When starting fatiguing stimulation at matching forces (i.e. lower stimulation frequency with CK‐2066260): force was decreased by ∼50% with and by ∼75% without CK‐2066260; [Mg 2+]i was increased by ∼10% with and ∼32% without CK‐2066260, reflecting a larger decrease in [ATP] in the latter. The glycogen content in in situ stimulated rat muscles fatigued by repeated contractions at matching forces was about two times higher with than without CK‐2066260. Voluntary exercise capacity, assessed by rats performing rotarod exercise and treadmill running, was improved in the presence of CK‐2066260. CK‐2066260 treatment also increased skeletal muscle fatigue resistance and exercise performance in a rat model of peripheral artery insufficiency. In conclusion, we demonstrate that the FSTA CK‐2066260 mitigates skeletal muscle fatigue by reducing the metabolic cost of force generation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1113/jp278235

Cites

Statistics

Figures

Figure 1 The myofibrillar Ca2+ sensitizer CK‐2066260 counteracts the fatigue‐induced force loss Representative force records from single FDB fibres during repeated tetanic stimulation (70 Hz, 350 ms given at 5 s interval) with addition of either CK‐2066260 (A) or caffeine (C) at the times indicated by the horizontal bars. B and D, force and [Ca2+]i in the first tetanus (a), when force was decreased to 40% of the initial (b), early (c) and end (d) of exposure to CK‐2066260 or caffeine, respectively. E, mean data (±SEM) show that CK‐2066260 superfusion resulted in a sustained decrease in tetanic [Ca2+]i and an increase in force (filled circles, n = 3–4 fibres from 4 mice), whereas caffeine induced a transient increase followed by a decrease of both tetanic [Ca2+]i and force (open circles, n = 5–6 fibres from 3 mice). # and *, P < 0.05 vs. the value immediately before application of CK‐2066260 or caffeine, respectively; one‐way repeated measures ANOVA.
Figure 1 The myofibrillar Ca2+ sensitizer CK‐2066260 counteracts the fatigue‐induced force loss Representative force records from single FDB fibres during repeated tetanic stimulation (70 Hz, 350 ms given at 5 s interval) with addition of either CK‐2066260 (A) or caffeine (C) at the times indicated by the horizontal bars. B and D, force and [Ca2+]i in the first tetanus (a), when force was decreased to 40% of the initial (b), early (c) and end (d) of exposure to CK‐2066260 or caffeine, respectively. E, mean data (±SEM) show that CK‐2066260 superfusion resulted in a sustained decrease in tetanic [Ca2+]i and an increase in force (filled circles, n = 3–4 fibres from 4 mice), whereas caffeine induced a transient increase followed by a decrease of both tetanic [Ca2+]i and force (open circles, n = 5–6 fibres from 3 mice). # and *, P < 0.05 vs. the value immediately before application of CK‐2066260 or caffeine, respectively; one‐way repeated measures ANOVA.CC BY-NC · PubMed Central
Figure 2 CK‐2066260 reduces the energy utilization and increases endurance during repeated tetanic contractions A, peak force and tetanic [Ca2+]i show better endurance in CK‐2066260‐treated (red symbols) vs. untreated control (black symbols) fibres when starting at the same force (n = 5 fibres per group from 5 mice). Increased force and [Ca2+]i after the 100th tetanus in CK‐2066260‐treated fibres was due to increasing the frequency to 50 Hz. Representative force and mag‐indo‐1 records during stimulation with matched initial forces obtained from a control (B) and a CK‐2066260‐treated (C) FDB fibre, and mean data from these experiments (D, n = 5 fibres per group from 4 mice). E, CK‐2066260‐treated and untreated FDB fibres showed similar declines in force during stimulation at maximal force (n = 3 fibres per group from 3 mice). F, rat hindlimb muscles treated with CK‐2066260 required lower stimulation frequency (25 Hz, n = 13) than muscles of vehicle‐treated rats (50 Hz, n = 13) to achieve equivalent forces during repeated tetanic stimulation (i.e. area under the curve, AUC), whereas forces of vehicle‐treated rats were lower with 25 Hz stimulation (n = 11). Representative PAS‐stained cross‐sections of medial gastrocnemius muscles (G) and percentage of positively PAS‐stained area (H) of unstimulated control muscles (n = 6), muscles of CK‐2066260‐treated rats stimulated with 25 Hz tetani (n = 5), and vehicle‐treated rats stimulated with 50 Hz tetani (n = 5) and 25 Hz tetani (n = 6). Data are means ± SEM, with individual data points shown in F and H. ** P < 0.01, *** P < 0.001, CK‐2066260‐treated vs. vehicle‐treated stimulated muscles with unpaired t test (A and D) or one‐way ANOVA (F and H).
Figure 2 CK‐2066260 reduces the energy utilization and increases endurance during repeated tetanic contractions A, peak force and tetanic [Ca2+]i show better endurance in CK‐2066260‐treated (red symbols) vs. untreated control (black symbols) fibres when starting at the same force (n = 5 fibres per group from 5 mice). Increased force and [Ca2+]i after the 100th tetanus in CK‐2066260‐treated fibres was due to increasing the frequency to 50 Hz. Representative force and mag‐indo‐1 records during stimulation with matched initial forces obtained from a control (B) and a CK‐2066260‐treated (C) FDB fibre, and mean data from these experiments (D, n = 5 fibres per group from 4 mice). E, CK‐2066260‐treated and untreated FDB fibres showed similar declines in force during stimulation at maximal force (n = 3 fibres per group from 3 mice). F, rat hindlimb muscles treated with CK‐2066260 required lower stimulation frequency (25 Hz, n = 13) than muscles of vehicle‐treated rats (50 Hz, n = 13) to achieve equivalent forces during repeated tetanic stimulation (i.e. area under the curve, AUC), whereas forces of vehicle‐treated rats were lower with 25 Hz stimulation (n = 11). Representative PAS‐stained cross‐sections of medial gastrocnemius muscles (G) and percentage of positively PAS‐stained area (H) of unstimulated control muscles (n = 6), muscles of CK‐2066260‐treated rats stimulated with 25 Hz tetani (n = 5), and vehicle‐treated rats stimulated with 50 Hz tetani (n = 5) and 25 Hz tetani (n = 6). Data are means ± SEM, with individual data points shown in F and H. ** P < 0.01, *** P < 0.001, CK‐2066260‐treated vs. vehicle‐treated stimulated muscles with unpaired t test (A and D) or one‐way ANOVA (F and H).CC BY-NC · PubMed Central
Figure 3 Effect of CK‐2066260 on muscle performance in healthy rats and after femoral artery ligation (FAL) Rotarod time to fall (vehicle‐treated, n = 13; CK‐2066260‐treated, n = 7) (A) and treadmill running time until exhaustion (n = 10 per group) (B). C, CK‐2066260 treatment increased the fatigue resistance in situ under FAL over a 10 min period of repeated contractions (FAL rats treated with CK‐2066260, n = 8; vehicle‐treated FAL rats, n = 16). D, accumulated force throughout repeated stimulation in situ (AUC, area under the curve). E, 2 weeks after bilateral FAL, rats treated with CK‐2066260 (n = 14) had longer treadmill run times until exhaustion than vehicle‐treated rats. Data are expressed as means ± SEM, and individual data points are shown in A, B, D and E. * P < 0.05 and ** P < 0.01, with paired (B) or unpaired t tests (A, D and E).
Figure 3 Effect of CK‐2066260 on muscle performance in healthy rats and after femoral artery ligation (FAL) Rotarod time to fall (vehicle‐treated, n = 13; CK‐2066260‐treated, n = 7) (A) and treadmill running time until exhaustion (n = 10 per group) (B). C, CK‐2066260 treatment increased the fatigue resistance in situ under FAL over a 10 min period of repeated contractions (FAL rats treated with CK‐2066260, n = 8; vehicle‐treated FAL rats, n = 16). D, accumulated force throughout repeated stimulation in situ (AUC, area under the curve). E, 2 weeks after bilateral FAL, rats treated with CK‐2066260 (n = 14) had longer treadmill run times until exhaustion than vehicle‐treated rats. Data are expressed as means ± SEM, and individual data points are shown in A, B, D and E. * P < 0.05 and ** P < 0.01, with paired (B) or unpaired t tests (A, D and E).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 46 · Cited by 41

Metadata

Authors
Cheng, A. J., Hwee, D. T., Kim, L. H., Durham, N., Yang, H. T., Hinken, A. C., Kennedy, A. R., Terjung, R. L., Jasper, J. R., Malik, F. I., & Westerblad, H.
Affiliations
  • Karolinska Institutet (SE)
  • Cytokinetics (United States) (US)
  • University of Missouri (US)
Corresponding author
Westerblad, Håkan
Venue
The Journal of Physiology
Publisher
Wiley
Published
2019-07-17
Volume
597
Issue
17
Pages
4615-4625
ISSN
  • 0022-3751 (ISSN-L)
  • 1469-7793
OpenAlex
W2954950504
Cited by
41
References
46
Citations by year
2026: 3 · 2025: 4 · 2024: 12 · 2023: 2 · 2022: 2 · 2021: 8 · 2020: 6 · 2019: 4
FWCI
1.74
Type
journal article
Language
en
Open access
Locations
  • The Journal of Physiology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Vetenskapsrådet (2018‐02576)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
Keywords
muscle fatigue, fatigue resistance, intracellular magnesium, ATP demand, exercise intolerance, muscular endurance
MeSH terms
Animals, Calcium, Female, Glycogen, Male, Mice, Inbred C57BL, Muscle Contraction, Myofibrils, Physical Conditioning, Animal, Troponin, Rats, Sprague-Dawley, Muscle Fibers, Fast-Twitch, Muscle Fatigue, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction. https://app.cochat.ai/papers/10.1113/jp278235
The paper
Cheng, A. J., Hwee, D. T., Kim, L. H., Durham, N., Yang, H. T., Hinken, A. C., Kennedy, A. R., Terjung, R. L., Jasper, J. R., Malik, F. I., & Westerblad, H. (2019). Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction. The Journal of Physiology. https://doi.org/10.1113/jp278235

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.